HUP9702387A1 - Neisseria meningitidis proteináz-K-rezisztens felszíni fehérjéje - Google Patents

Neisseria meningitidis proteináz-K-rezisztens felszíni fehérjéje

Info

Publication number
HUP9702387A1
HUP9702387A1 HU9702387A HUP9702387A HUP9702387A1 HU P9702387 A1 HUP9702387 A1 HU P9702387A1 HU 9702387 A HU9702387 A HU 9702387A HU P9702387 A HUP9702387 A HU P9702387A HU P9702387 A1 HUP9702387 A1 HU P9702387A1
Authority
HU
Hungary
Prior art keywords
neisseria meningitidis
surface protein
proteinase
kda
neisseriameningitidis
Prior art date
Application number
HU9702387A
Other languages
English (en)
Inventor
Bernard R. Brodeur
Jesée Hamel
Denis Martin
Clément Rioux
Original Assignee
Biochem Vaccines Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26669758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9702387(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biochem Vaccines Inc. filed Critical Biochem Vaccines Inc.
Publication of HUP9702387A1 publication Critical patent/HUP9702387A1/hu
Publication of HUP9702387A3 publication Critical patent/HUP9702387A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát a Neisseria meningitidis mikrőőrganizműsőkfelszínén elhelyezkedő, erősen kőnzervált, imműnőlógiailaghőzzáférhető antigén képezi. A találmány szerinti antigén a Neisseriameningitidis őkőzta betegségek kezelésére, megelőzésére ésfelismerésére alkalmas, új imműnterápiás, prőfilaktikűs ésdiagnősztikai anyagők előállításának az alapjáűl szőlgál.Közelebbről, a találmány tárgyát egy prőteináz-K-rezisztens Neisseriameningitidis felszíni fehérje képezi, amelynek mőlekűlatömege 22 kDa-nak adódik, az ennek megfelelő nűkleőtid-, és az abból levezethetőaminősavszekvencia; rekőmbináns DNS-eljárásők a Neisseria meningitidis22 kDa felszíni fehérje előállítására; antitestek, amelyek kötődnek aNeisseria meningitidis 22 kDa felszíni fehérjéhez; valamint eljárásőkés készítmények a Neiseria meningitidis őkőzta betegségekfelismerésére, kezelésére és megelőzésére.ŕ
HU9702387A 1995-03-17 1996-03-15 Proteinase k resistant surface protein of neisseria meningitidis HUP9702387A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40636295A 1995-03-17 1995-03-17
US198395P 1995-08-04 1995-08-04

Publications (2)

Publication Number Publication Date
HUP9702387A1 true HUP9702387A1 (hu) 1998-05-28
HUP9702387A3 HUP9702387A3 (en) 1999-09-28

Family

ID=26669758

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702387A HUP9702387A3 (en) 1995-03-17 1996-03-15 Proteinase k resistant surface protein of neisseria meningitidis

Country Status (25)

Country Link
EP (1) EP2241625A1 (hu)
JP (3) JPH11500624A (hu)
KR (1) KR100361562B1 (hu)
AP (1) AP1027A (hu)
AR (2) AR002970A1 (hu)
AU (1) AU716225B2 (hu)
BR (1) BR9607651B8 (hu)
CA (1) CA2215161C (hu)
CZ (2) CZ298052B6 (hu)
EA (1) EA001789B1 (hu)
GE (1) GEP20032977B (hu)
HK (1) HK1014991A1 (hu)
HU (1) HUP9702387A3 (hu)
IL (1) IL117483A (hu)
MX (1) MX9707061A (hu)
NO (1) NO326425B1 (hu)
NZ (1) NZ303118A (hu)
OA (1) OA10742A (hu)
PL (1) PL184373B1 (hu)
RO (1) RO117924B1 (hu)
SI (1) SI9620035A (hu)
SK (1) SK287456B6 (hu)
TR (1) TR199700971T1 (hu)
TW (1) TW520375B (hu)
WO (1) WO1996029412A1 (hu)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463097A (en) 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
NZ541361A (en) 1998-05-01 2008-04-30 Inst Genomic Research Neisseria meningitidis antigens and compositions relating to SEQ ID Nos:2916, 2918 and 2920
AU2107400A (en) * 1999-01-15 2000-08-01 Smithkline Beecham Biologicals (Sa) Neisseria meningitidis antigen
ES2298128T3 (es) 1999-02-22 2008-05-16 Health Protection Agency Composiciones de vacuna neisseriana y metodos.
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
MXPA01010924A (es) 1999-04-30 2002-05-06 Chiron Spa Antigenos de neisseria conservados.
GB9910168D0 (en) * 1999-04-30 1999-06-30 Chiron Spa Conserved antigens
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
AU2013203304B2 (en) * 1999-05-19 2014-10-09 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
EP2275553B1 (en) * 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2507100T3 (es) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
BR0108711A (pt) 2000-02-28 2004-06-22 Chiron Spa Expressão heteróloga de proteìnas de neisseria
AU2001280883A1 (en) 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
KR100982204B1 (ko) 2001-12-12 2010-09-14 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 클라미디아 트라코마티스에 대한 면역화
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
SI2255826T1 (sl) 2002-08-02 2016-07-29 Glaxosmithkline Biologicals S.A. Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
GB0220197D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Refolding method
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
SI1549338T1 (sl) 2002-10-11 2011-04-29 Novartis Vaccines & Diagnostic Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DE602004028262D1 (de) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
ES2337309T5 (es) 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
BRPI0909037B8 (pt) 2008-03-03 2021-05-25 Irm Llc compostos moduladores da atividade de tlr, e composição farmacêutica
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CN103897045A (zh) 2009-01-12 2014-07-02 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
JP2013522287A (ja) 2010-03-18 2013-06-13 ノバルティス アーゲー 血清群ｂ髄膜炎菌のためのアジュバント添加ワクチン
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2790167C (en) 2010-03-30 2021-02-09 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
AU2012272652B2 (en) 2011-06-24 2017-06-01 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
BR112014019166A2 (pt) 2012-02-02 2017-07-04 Novartis Ag promotores para expressão aumentada de proteína em meningococos
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
CA2876138C (en) 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
HUE052293T2 (hu) 2014-02-28 2021-04-28 Glaxosmithkline Biologicals Sa Módosított fHbp meningococcus-polipeptidek
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
MX2020010913A (es) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
IL307519A (en) 2021-04-09 2023-12-01 Celldex Therapeutics Inc Antibodies against ILT4, anti-ILT4\PD-L1 bispecific antibody and their uses
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
WO1994005703A1 (en) * 1992-08-31 1994-03-17 Global Tek, Inc. Monoclonal antibody to cell surface protein of the bacterium neisseria meningitidis

Also Published As

Publication number Publication date
RO117924B1 (ro) 2002-09-30
JP4109939B2 (ja) 2008-07-02
PL184373B1 (pl) 2002-10-31
EA199700248A1 (ru) 1998-04-30
SK125597A3 (en) 1998-06-03
WO1996029412A1 (en) 1996-09-26
MX9707061A (es) 1998-08-30
AR052377A2 (es) 2007-03-14
NZ303118A (en) 2000-07-28
AU716225B2 (en) 2000-02-24
TR199700971T1 (xx) 1998-04-21
OA10742A (en) 2002-12-10
PL322363A1 (en) 1998-01-19
SK287456B6 (sk) 2010-10-07
NO974264D0 (no) 1997-09-15
CZ298052B6 (cs) 2007-06-06
BR9607651B8 (pt) 2014-08-05
JP4271231B2 (ja) 2009-06-03
HK1014991A1 (en) 1999-11-19
AP1027A (en) 2001-11-23
NO326425B1 (no) 2008-12-01
IL117483A (en) 2008-03-20
CZ298646B6 (cs) 2007-12-05
CA2215161A1 (en) 1996-09-26
EA001789B1 (ru) 2001-08-27
GEP20032977B (en) 2003-05-27
SI9620035A (sl) 1998-12-31
AR002970A1 (es) 1998-05-27
JP2007159583A (ja) 2007-06-28
BR9607651B1 (pt) 2011-02-08
CZ291497A3 (cs) 1998-01-14
CA2215161C (en) 2012-10-30
HUP9702387A3 (en) 1999-09-28
KR100361562B1 (ko) 2004-05-20
TW520375B (en) 2003-02-11
EP2241625A1 (en) 2010-10-20
AU4934396A (en) 1996-10-08
NO974264L (no) 1997-11-13
JP2003189879A (ja) 2003-07-08
BR9607651A (pt) 1998-11-17
IL117483A0 (en) 1996-07-23
JPH11500624A (ja) 1999-01-19
KR19980703099A (ko) 1998-10-15
AP9701118A0 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
HUP9702387A1 (hu) Neisseria meningitidis proteináz-K-rezisztens felszíni fehérjéje
Lee et al. Porphyromonas (Bacteroides) gingivalis fimbrillin: size, amino-terminal sequence, and antigenic heterogeneity
NO20070618L (no) Forbindelser og fremgangsmater for immunterapi og diagnose av tuberkulose.
TR199701537T1 (xx) HSP70 ailesinin streptokokal �s� �ok protein �yeleri.
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
CY1106875T1 (el) Αντιγονικα πεπτιδια απο neisseria
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
HUP0004639A2 (hu) Chlamydia fehérje, génszekvencia és ezek alkalmazása
ATE460484T1 (de) 85 kda antigen von neisseria
DK0494294T3 (da) Bakterielle stressproteiner
JP2000507245A (ja) Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓペプチドを含む免疫原性組成物および方法
ATE235916T1 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
CA2217522A1 (en) Isolated frpb nucleic acid molecule and vaccine
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
SE9901601D0 (sv) Peptides from the TT virus sequence and monospecific antibodies binding to the TT virus
AUPN712795A0 (en) Recombinant vaccines
ATE246002T1 (de) Membranproteine von leptospira
DE69841131D1 (de) Multiple Sklerose assoziierte retrovirale Nucleinsäuren und entsprechende Nucleotidfragmente für die Diagnostik, Prophylaxe und Therapie
MX9709557A (es) Miembros de proteinas de choque termico estreptococales de la familia hsp7o.
Uchiyama Sequence Analysis of the Gene Encoding a Spotted Fever Group‐Specific Intracytoplasmic Protein PS120 of Rickettsia japonica
VALES PURIFICATION AND SUBUNIT ANALYSIS OF EXONUCLEASE VII OF E. COLI; ISOLATION OF NEGATIVE-XSEB STRAINS AND LAMBDA-DXSEA TRANSDUCING PHAGE.
TH14552EX (th) ลำดับทางพันธุกรรมสำหรับ แอนติเจน ir-95 ชนิด 90k ที่พบร่วมกับเนื้องอก
TH14552A (th) ลำดับทางพันธุกรรมสำหรับ แอนติเจน ir-95 ชนิด 90k ที่พบร่วมกับเนื้องอก

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ID BIOMEDICAL CORPORATION, CA

Free format text: FORMER OWNER(S): BIOCHEM VACCINES INC., CA; BIOCHEM PHARMA INC., CA

FD9A Lapse of provisional protection due to non-payment of fees